Altimmune Stock: is Its GLP-1 Drug Poised to Rival Ozempic?

Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? Written by Jea Yu | Reviewed by Shannon Tokheim July 3, 2024 Share Link copied to clipboard. Key Points Altimmune released the results of its Phase 2 Clinical Trials for pemvidutid
Read more...